“We expect that, over time here, to provide us some tailwind.”

In context

“some share gains here due to launch of this product? Rainer Blair: Sure, Vijay. We -- on the gene reading side of the house, we do still see the markets softer, as -- particularly in the smaller customer, emerging biotech segment, we see less activity. While the funding improved, those customers are still prioritizing their project quite a bit. And so we're seeing a bit less consumption in that area. Now in gene editing, of course, that's a different story, where we see a great deal of CRISPR and Guide RNA and other types of solutions doing very well. Having said that, and coming back to our new product launch here with Rapid Genes, we're very excited about that. This will offer whole genes to our customers at a quality and a turnaround time, which is highly differentiated in the market. We expect that, over time here, to provide us some tailwind. So we're very pleased here with how IDT is performing in this environment. Vijay Kumar: Understood. And maybe, Matt, one for you. Your Q4 operating margin assumption, it came down a tad versus the prior. I think we're looking at low-30s exit rates. Is there some timing of expenses or anything changed on margin assumption? And if it is, any change in investments and implications here as we look at incremental margins for fiscal '25? Matt McGrew: Yeah, I mean, our full year margin didn't change, approximately 29%. Q4 will be at approximately 30%. I mean, I think it's probably a function of a couple of things. One, we're going to have -- we anticipate at least lower revenue in respiratory in Q4. Obviously, that has some margin implications to it. I think we did have a little bit of sort of t”